Preclinical Assets Industry Forecast to Hit $9.28 Billion by 2029 With a Strong 9.8% CAGR

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Future Market Size Estimation For The Preclinical Assets Market Covering 2025–2034?

The preclinical assets market size has experienced robust expansion in recent years. It is projected to climb from $5.87 billion in 2024 to $6.38 billion in 2025, at a compound annual growth rate (CAGR) of 8.8%. The growth observed in prior periods is attributable to drug development needs, breakthroughs in biotechnology, regulatory requirements, increased research funding, and cooperative research initiatives.

The preclinical assets market is anticipated to experience robust expansion over the next few years, with its size forecast to reach $9.28 billion in 2029, achieving a compound annual growth rate (CAGR) of 9.8%. This increase during the forecast period is primarily attributed to advancements in precision medicine and personalized therapies, the integration of AI and machine learning, the expansion of biobanking, a sharpened focus on rare diseases, and various government initiatives and funding. Significant trends expected in this timeframe include the emergence of advanced imaging techniques, 3D organoid models, multi-omics integration, enhanced predictive models, alongside automation and high-throughput screening.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12600&type=smp

What Are The Emerging Market Drivers Creating New Opportunities In The Preclinical Assets Industry?

The expanding field of drug discovery is anticipated to boost the preclinical asset market moving forward. Drug discovery is defined as the procedure of identifying chemical compounds that possess medicinal properties, and it involves the uncovering of new potential medications. In this context, preclinical assets are crucial, providing vital information and proof to assist in selecting molecules suitable for clinical development as prospective candidates. A notable illustration of this trend is observed in the European pharmaceutical industry; as reported in June 2023 by the European Federation of Pharmaceutical Industries and Associations (EFPIA), a Belgium-based entity representing the pharmaceutical sector, the industry’s production saw significant growth, escalating from $352.48 billion in 2021 to $369.95 billion in 2022. Consequently, the heightened activity in drug discovery is fueling the expansion of the preclinical assets market.

What Are The Leading Segments Analyzed In The Preclinical Assets Market?

The preclinical assetsmarket covered in this report is segmented –

1) By Service: Bioanalysis And DMPK (Drug Metabolism And Pharmacokinetic) Studies; Toxicology Testing; Compound Management; Safety Pharmacology; Other Services

2) By Model Type: Patient Derived Organoid (PDO) Model; Patient Derived Xenograft Model

3) By End User: Biopharmaceutical Companies; Government Institutes; Other End-Users

Subsegments:

1) By Bioanalysis And DMPK (Drug Metabolism And Pharmacokinetic) Studies: Pharmacokinetics (PK) Studies; Pharmacodynamics (PD) Studies; Bioanalytical Method Development

2) By Toxicology Testing: Acute Toxicity Testing; Chronic Toxicity Testing; Genotoxicity Testing; Carcinogenicity Testing

3) By Compound Management: Compound Library Management; Sample Storage And Retrieval; High-Throughput Screening Support

4) By Safety Pharmacology: Cardiovascular Safety Assessments; Neurotoxicity Evaluations; Respiratory Safety Evaluations

5) By Other Services: Regulatory Support; Preclinical Study Design And Consulting; Custom Assay Development

How Are Trends Influencing The Preclinical Assets Market?

Product innovations represent a significant trend gaining traction within the preclinical assets market. Major companies operating in the preclinical assets market are concentrating on developing novel products and solutions to bolster their market standing and achieve a competitive edge. For instance, in April 2022, Charles River Laboratories International, a US-based pharmaceutical company specializing in diverse preclinical and clinical laboratories, and Valo Health Inc., a US-based technology company built to transform drug discovery, introduced Logica. This artificial intelligence (AI)-powered drug solution directly translates clients’ biological insights into optimized preclinical assets. Logica leverages Charles River’s advanced preclinical knowledge and Valo’s AI-powered Opal Computational Platform, offering clients a transformed drug discovery experience through a single integrated offering that efficiently translates targets to candidate nomination. By collaborating with Valo, Charles River combines its laboratory expertise with molecular design technology, thereby revolutionizing the industry to provide its clients with highly qualified leads and candidates, while also linking client costs to value creation.

Which Major Firms Are Strengthening Their Position In The Preclinical Assets Industry?

Major companies operating in the preclinical assets market include Laboratory Corporation of America, IQVIA Inc., ICON PLC, Eurofins Scientific SE, PPD Inc., SGS SA, WuXi AppTec Co. Ltd., Intertrek Group PLC, Charles River Laboratories International Inc., Medpace Inc., Pharmaron Beijing Co. Ltd., Evotec SE, GenScript Biotech Corporation, Inotiv Inc., SRI International Inc., Shanghai Medicilon Inc., Biocytogen Pharmaceuticals Beijing Co. Ltd., AmplifyBio LLC, BioReliance Corporation, Pharmalegacy Laboratories Co. Ltd., Precigen Inc., ReproCELL Incorporated, InSphero AG, Crown Bioscience Inc., Comparative Biosciences Inc., TCG Lifesciences Pvt. Ltd., InVivo Biosystems, Pharmatest Services Ltd, Domainex Limited, Viroclinics Xplore

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/preclinical-assets-global-market-report

Which Geographies Are Emerging As Strong Markets For The Preclinical Assets Industry?

North America was the largest region in the preclinical assets market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the preclinical assets market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request A Customized Version Of The Preclinical Assets Market Report:

https://www.thebusinessresearchcompany.com/customise?id=12600&type=smp

Browse Through More Reports Similar to the Global Preclinical Assets Market 2025, By The Business Research Company

Preclinical Imaging Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/preclinical-imaging-global-market-report

Preclinical Cro Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/preclinical-cro-global-market-report

Lessors Of Nonfinancial Intangible Assets Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/lessors-of-nonfinancial-intangible-assets-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795